Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab second-line treatment study in advanced EGFR/ALK wild-type non-small cell lung cancer
ChiCTR1900027220Phase 4Not yet recruiting
- Sponsor
- Anqing Hospital of the PLA Navy
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Anqing Hospital of the PLA Navy. Primary endpoint: Progression-free survival. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900027220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027220.